Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Schizophrenia Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/S0920-9964(97)82189-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Schizophrenia After Prenatal Famine

  1997cited by this paper
• Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.

  1996cited by this paper
• D-cycloserine added to clozapine for patients with schizophrenia.

  1996cited by this paper
• Rhesus incompatibility as a risk factor for schizophrenia in male adults.

  1996cited by this paper
• Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis.

  1995cited by this paper
• Glutamate receptor dysfunction and schizophrenia.

  1995cited by this paper
• Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.

  1995cited by this paper
• Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.

  1995cited by this paper
• The phencyclidine-glutamate model of schizophrenia.

  1995cited by this paper
• N-acetylaspartate in neuropsychiatric disorders.

  1995cited by this paper
• Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

  1994cited by this paper
• CSF dopamine beta-hydroxylase in schizophrenia: associations with premorbid functioning and brain computerized tomography scan measures.

  1994cited by this paper
• Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways.

  1993cited by this paper
• N-acetyl-aspartylglutamate modulation of N-methyl-D-aspartate-stimulated [3H]norepinephrine release from rat hippocampal slices.

  1993cited by this paper
• The NMDA receptor antagonist CPP abolishes neurogenic “wind-up pain” after intrathecal administration in humans.

  1992cited by this paper
• Ventricular Enlargement in Schizophrenia

  1992cited by this paper
• A Viral-Anatomical Explanation of Schizophrenia

  1991cited by this paper
• Computed tomography measurements of brain density in Schizophrenia.

  1991cited by this paper
• Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies.

  1991cited by this paper
• Recent advances in the phencyclidine model of schizophrenia.

  1991cited by this paper
• Amino acid patterns in schizophrenia: some new findings.

  1990cited by this paper
• Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities.

  1990cited by this paper
• Physiological and pathophysiological roles of excitatory amino acids during central nervous system development.

  1990cited by this paper
• Excitotoxic amino acids and neuropsychiatric disorders.

  1990cited by this paper
• Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imaging.

  1990cited by this paper
• Genetic and perinatal determinants of structural brain deficits in schizophrenia.

  1989cited by this paper
• A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine.

  1989cited by this paper
• Positron emission tomography in aging and dementia: effect of cerebral atrophy.

  1987cited by this paper
• Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid.

  1987cited by this paper
• An endogenous ligand of the brain σ/PCP receptor antagonizes NMDA-induced neurotransmitter release

  1987cited by this paper
• Cerebrospinal fluid amino acid concentrations in chronic schizophrenia.

  1987cited by this paper
• Current outcome in schizophrenia: women vs men

  1986cited by this paper
• Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls.

  1985cited by this paper
• Lateral ventricular enlargement associated with persistent unemployment and negative symptoms in both schizophrenia and bipolar disorder.

  1984cited by this paper
• Evidence for an endogenous peptide ligand for the phencyclidine receptor.

  1984cited by this paper
• Cerebral glutamate, neuroleptic drugs and schizophrenia: increase of cerebrospinal fluid glutamate levels and decrease of striate body glutamate levels following sulpiride treatment in rats.

  1983cited by this paper
• Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy.

  1983cited by this paper
• Cerebral ventricular size in twins discordant for schizophrenia.

  1982cited by this paper
• Negative symptoms in schizophrenia

  1982cited by this paper
• Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction.

  1982cited by this paper
• Computed tomography in schizophreniform disorder and other acute psychiatric disorders.

  1982cited by this paper
• Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms.

  1982cited by this paper
• Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.

  1980cited by this paper
• Poor premorbid adjustment and CT scan abnormalities in chronic schizophrenia.

  1980cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper
• neurotransmitters: from basic science to

  year unknowncited by this paper

• Molecular Mechanisms Provide a Landscape for Biomarker Selection for Schizophrenia and Schizoaffective Psychosis

  2023cites this paper
• Glutamate-mediated excitotoxicity in schizophrenia: a review.

  2014influential citation
• D-serine: the right or wrong isoform?

  2011cites this paper
• Influence of the NR3A subunit on NMDA receptor functions.

  2010cites this paper
• Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.

  2003cites this paper
• The delayed effects of DTG and MK-801 on latent inhibition in a conditioned taste-aversion paradigm.

  2000cites this paper
• GABA and brain abnormalities in schizophrenia.

  1998cites this paper
• The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

  1998cites this paper